@FiercePharma: Study: Elephants rarely get cancer--and that could boost human oncology research. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi's Kansas City, MO, plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce
@CarlyHFierce: Backlash rages on over Purdue's pediatric OxyContin approval. Story | Follow @CarlyHFierce
> Johnson & Johnson's ($JNJ) prostate cancer treatment Zytiga won approval from the Scottish Medicines Consortium, which means it can be routinely used in that country; the drug still lacks routine approval in England and Wales. Release
> Novartis ($NVS) unveiled new data showing that a majority of psoriasis patients using Cosentyx were able to maintain clear or almost clear skin for three years. Release
> Amgen's ($AMGN) Prolia delivered larger gains in bone-mineral density than the IV bisphosphonate drug zoledronic acid in postmenopausal women with osteoporosis who'd previously been treated with bisphosphonates. Release
> New U.S. drug approvals promise better second-half results for Indian drugmakers, analysts said, compared with the first six months of this year. Report
Medical Device News
@FierceMedDev: ICYMI Friday: Procyrion raises $10M to get minimally invasive mini heart pump in the clinic. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI last week from #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2
@EmilyWFierce: The latest from Advera Health Analytics on Alzheimer's drug safety. ICYMI from FiercePharma | Follow @EmilyWFierce
> NuVasive gets FDA blessing for spinal cord surgical device. Report
> Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More
> Neurosurgeons hope brain implants can be used to treat array of mental disorders. Article
Biotech News
@FierceBiotech: Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. News | Follow @FierceBiotech
@JohnCFierce: How many big swings and misses does John Lechleiter get at $LLY? | Follow @JohnCFierce
@DamianFierce: Tired of writing about $LLY today so here's a hypoglycemia deal you can read about yourself. Press release | Follow @DamianFierce
> Novartis buys a bigger stake in Gamida, stopping short of a $600M plunge. Report
> Lilly pulls the plug on a would-be blockbuster in its latest pipeline peril. Story
> Voyager braves turbulent market waters with an $86M gene therapy IPO. Article
Animal Health News
> Study: Elephants rarely get cancer--and that could boost human oncology research. More
> Ceva urges mass vaccination against bird flu at global animal-health gathering. Story
> FDA seeks comments on potential scheduling change for ketamine. Item
> California sets strictest U.S. standards for antibiotics use in livestock. Article
> CalTech team creates one-time contraceptive vaccine for feral animals. Report
Biotech IT News
> NIH gives UCSF $10M to build mobile data collection platform. News
> GSK finds 21M mentions of its drugs in trawl of social media. Report
> ResearchKit-enabled project sets out to track real-world effectiveness of hep C drugs. Story
> UBiome taps Apple ecosystem to broaden microbiome data-gathering drive. Article
> Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet. More
Pharma Marketing News
> Baxalta joins biosim makers eyeing a piece of AbbVie's Humira. More
> Biogen's top commercial exec leaves amid Tecfidera sales trouble. Report
> Roche leads the pack at ECTRIMS with standout data on new MS drug. Item
> Bill seeks to add nurse practitioners, PAs to Sunshine Act reporting. Story
> Pharma's digital desires thwarted by clunky organizations, lack of skilled employees. Article
And Finally... Merck KGaA says it's betting its cancer pipeline can rescue it from a decline in sales of its top-selling multiple sclerosis drug Rebif. Report